Tom Hartman is the newly appointed CEO and President of ISPE, beginning in this role on 1 June 2020. He most recently served as the Vice President of GMP Operations, Biopharm CMC, for GlaxoSmithKline, with responsibility for the biopharmaceutical API and Drug Product clinical supply chain including cell banks, raw materials, manufacturing operations, engineering, validation, quality control and compliance functions, for internal and external CMO/CRO’s. Tom joined GSK in 2001 in the capacity of Director, Biopharmaceutical Facilities and Systems with responsibilities for Engineering, IT Systems, and Validation for both the US & UK Biopharmaceutical GMP and process development facilities. Following his appointment to Director Manufacturing Operations in 2004, he led a major engineering project to renovate and startup the GSK’s biopharmaceutical manufacturing facility in King of Prussia, PA. He was named Vice President GMP Operations in 2006. Prior to joining GSK, Tom held senior positions in the US and expatriate roles in Europe in the specialty chemicals industry including responsibility for engineering, operations, production, and reliability programs to support manufacturing of raw materials and process intermediates for use in the food and drug industry, and commodity chemical businesses. He was elected to the ISPE Board of Directors in 2013 and is currently ISPE Board Vice Chair, and incoming 2020/21 ISPE Board Chairman. Mr. Hartman earned a BME from Villanova University and an MBA from Eastern University and has been a Member of ISPE since 2001.